Iterum Therapeutics plc (ITRM) reported Wednesday that it entered into a Product Commercialization Agreement with EVERSANA Life Science Services, LLC for the commercialization of the Company's approved product, ORLYNVAH.
Pursuant to the Agreement, EVERSANA will provide sales and commercial operations services to the company in the U.S., as well as deliver marketing, logistics, channel management, regulatory, medical affairs and other services related to the commercialization of ORLYNVAH in the U.S.
ORLYNVAH, the first oral penem antibiotic available in the U.S., will be commercially launched in the U.S. by the fourth quarter of 2025.
ORLYNVAH will be made available to prescribers and patients with limited or no oral options to handle hard-to-treat uncomplicated urinary tract infections (uUTI).
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.